Humalog 2003 ml KwikPen

Humalog 200 3 ml KwikPen is a rapid-acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

Established / FDA-approved uses

• Type 1 diabetes mellitus, as part of a regimen that includes a longer-acting (basal) insulin, to control mealtime (postprandial) blood glucose rise.
• Type 2 diabetes mellitus, as mealtime/bolus insulin, alone or combined with a basal insulin and/or oral antidiabetic agents, when glycemic goals are not met with other therapy.

Other established uses

• Continuous subcutaneous insulin infusion via an insulin pump, in formulations approved for pump use.
• Intravenous use under close medical supervision (e.g. management of severe hyperglycemia or diabetic ketoacidosis in a hospital setting), only with appropriate glucose monitoring.

Humalog 200 3 ml KwikPen is not a substitute for individualized dose titration; the exact dose and timing must always be determined by a treating physician based on each patient's blood glucose monitoring, meal pattern, and activity level.

Each mL of injectable solution typically contains Humalog 200 3 ml KwikPen 100 units (U-100), or in higher-strength presentations 200 units (U-200), as the active ingredient, produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli. Inactive ingredients commonly include metacresol (preservative), glycerin, zinc oxide, and water for injection, with pH adjusted using agents such as sodium hydroxide or hydrochloric acid.

Humalog 200 3 ml KwikPen is a rapid-acting insulin analog created by reversing the natural sequence of two amino acids (lysine and proline) at positions 28 and 29 on the insulin B-chain. This modification reduces the tendency of insulin molecules to self-associate into hexamers, allowing faster absorption from the subcutaneous injection site than regular human insulin.

After subcutaneous injection, Humalog 200 3 ml KwikPen begins lowering blood glucose within about 15 minutes, reaches peak effect around 30 minutes to 1.5 hours, and has a duration of action of approximately 3 to 5 hours, which closely mimics the body's natural mealtime insulin response.

Humalog 200 3 ml KwikPen belongs to the therapeutic class of rapid-acting insulin analogs, a subclass of antidiabetic agents used for mealtime (prandial/bolus) glycemic control.

Mechanism of action

Humalog 200 3 ml KwikPen works by binding to insulin receptors on target tissues (primarily skeletal muscle and adipose tissue), stimulating glucose uptake, and by suppressing hepatic glucose production. It also promotes protein synthesis and inhibits lipolysis and proteolysis, replicating the physiological actions of endogenous insulin.

Pharmacokinetics

Absorption and time-action profile can vary with injection site, dose, blood flow, temperature, and physical activity.

Humalog 200 3 ml KwikPen is given by subcutaneous injection (syringe, prefilled pen, or insulin pump) shortly before or immediately after a meal, or intravenously in hospital settings under supervision. Do not inject into a vein or muscle unless specifically directed for IV use by a healthcare professional. Inspect the solution before use; it should be clear and colorless (regular formulations) — do not use if particulate matter or discoloration is seen. Do not mix with other insulins in the same syringe or vial unless specifically indicated and approved for co-administration, as this can alter the onset and duration of action.

Clinically significant interactions

• Oral antidiabetic agents, GLP-1 agonists: additive glucose-lowering effect; increased risk of hypoglycemia when combined with Humalog 200 3 ml KwikPen.
• Beta-blockers, clonidine, alcohol: may blunt or mask the warning signs and symptoms of hypoglycemia caused by Humalog 200 3 ml KwikPen, delaying recognition and treatment.
• Thiazolidinediones (e.g. pioglitazone): combination with Humalog 200 3 ml KwikPen is associated with increased risk of fluid retention and congestive heart failure, particularly in patients with pre-existing cardiac risk factors.
• Corticosteroids, thyroid hormone, estrogens, atypical antipsychotics, some diuretics: may reduce the glucose-lowering effect of Humalog 200 3 ml KwikPen, increasing hyperglycemia risk and requiring dose adjustment.
• ACE inhibitors, salicylates, MAO inhibitors, sulfonamide antibiotics: may enhance the blood-glucose-lowering effect of Humalog 200 3 ml KwikPen, increasing hypoglycemia risk.

Always inform the prescriber of all medicines being taken so the Humalog 200 3 ml KwikPen dose can be adjusted appropriately.

Most common / most serious

• Hypoglycemia — the most common and most serious adverse effect of Humalog 200 3 ml KwikPen; symptoms include sweating, tremor, palpitations, hunger, confusion, and, if severe and untreated, seizure, loss of consciousness, or death.

Other side effects

• Injection-site reactions: redness, swelling, itching, or pain.
• Lipodystrophy (lipohypertrophy or lipoatrophy) with repeated injection at the same site.
• Weight gain and peripheral edema.
• Allergic reactions ranging from local skin rash to, rarely, generalized allergy or anaphylaxis.
• Hypokalemia (low blood potassium) with excessive dosing.

Humalog 200 3 ml KwikPen does not cross the placenta in clinically significant amounts and is commonly used to manage diabetes during pregnancy, since good glycemic control is important for both mother and fetus. However, Humalog 200 3 ml KwikPen should be used only under close medical supervision, with the dose individualized and adjusted throughout pregnancy as insulin requirements typically change. Use only if clearly needed and as directed by a physician.

Limited data suggest Humalog 200 3 ml KwikPen is compatible with breastfeeding, as insulin is a normal component of breast milk and is broken down in the infant's digestive tract; however, breastfeeding mothers using Humalog 200 3 ml KwikPen may need dose adjustments and should be monitored by their physician.

Hypoglycemia

Humalog 200 3 ml KwikPen carries a significant risk of hypoglycemia, which can be life-threatening if severe. Risk is increased with dose errors, skipped or delayed meals, unplanned exercise, alcohol intake, or changes in insulin sensitivity. Because of its rapid onset, Humalog 200 3 ml KwikPen should be given close to mealtime; injecting without a following meal can precipitate hypoglycemia.

Do not use fixed/universal doses

The dose of Humalog 200 3 ml KwikPen must always be individualized and titrated by a physician based on regular blood glucose monitoring; never use a dose intended for another person or a generic "standard" dose.

Insulin mix-ups

Always check the vial or pen label before each injection of Humalog 200 3 ml KwikPen to avoid accidental mix-up with other insulin types or concentrations, which has caused serious dosing errors.

Do not mix insulins improperly

Do not mix Humalog 200 3 ml KwikPen with other insulins unless specifically instructed and approved for co-administration by the prescriber, as this may alter its rapid onset and time-action profile.

Hypoglycemia unawareness

In patients with long-standing diabetes, diabetic nerve disease, or those using beta-blockers, the usual warning symptoms of hypoglycemia from Humalog 200 3 ml KwikPen may be reduced or absent.

Illness, renal or hepatic impairment

Insulin requirements may change with acute illness, and with renal or hepatic impairment, requiring closer monitoring and dose adjustment.

Pump and injection site

Rotate injection sites and follow pump manufacturer instructions carefully; pump malfunction or set occlusion can rapidly lead to hyperglycemia and, in type 1 diabetes, diabetic ketoacidosis.

Overdose of Humalog 200 3 ml KwikPen relative to food intake, physical activity, or concurrent glucose-lowering therapy can cause hypoglycemia, which may range from mild (hunger, sweating, tremor, palpitations) to severe (confusion, seizure, unconsciousness). Mild hypoglycemia may be treated with oral fast-acting carbohydrate (e.g. glucose tablets or juice) as advised by a physician; severe hypoglycemia is a medical emergency requiring immediate glucose administration (intravenous glucose or glucagon) by trained personnel. Anyone experiencing signs of overdose or severe hypoglycemia after taking Humalog 200 3 ml KwikPen should seek immediate medical attention or contact emergency services; do not attempt unsupervised home treatment of severe symptoms.

Unopened Humalog 200 3 ml KwikPen vials, cartridges, or pens should be stored in a refrigerator (2°C to 8°C), protected from light, and not frozen; discard if it has been frozen. Once in use, Humalog 200 3 ml KwikPen may generally be kept at room temperature (below 30°C), away from direct heat and light, and should be discarded after the manufacturer-specified in-use period (commonly 28 days), even if some medicine remains. Keep out of reach of children.

Renal impairment

Insulin requirements for Humalog 200 3 ml KwikPen may be reduced in renal impairment due to decreased insulin clearance; closer glucose monitoring and dose adjustment are recommended.

Hepatic impairment

Insulin requirements may be reduced in hepatic impairment due to decreased gluconeogenesis and insulin metabolism; monitor glucose closely and adjust dose as needed.

Elderly

Use Humalog 200 3 ml KwikPen cautiously in elderly patients, with conservative dose titration, as they may be more susceptible to hypoglycemia and may have reduced ability to recognize or communicate hypoglycemic symptoms.

Pregnancy and lactation

See Pregnancy and Lactation section.

Humalog 200 3 ml KwikPen is generally used long-term as part of ongoing diabetes management, since diabetes mellitus is a chronic condition. There is no fixed treatment duration; therapy continues for as long as the physician determines mealtime insulin coverage is needed, with the regimen reviewed and adjusted periodically based on glycemic control.

Humalog 200 3 ml KwikPen is classified as a rapid-acting insulin analog within the broader class of antidiabetic/hypoglycemic agents (insulins).

Humalog 200 3 ml KwikPen acts by binding insulin receptors on muscle and fat cells, promoting cellular glucose uptake and glycogen synthesis, while suppressing hepatic glucose output, lipolysis, and proteolysis — the same core actions as endogenous insulin, but with a faster onset and shorter duration due to reduced self-aggregation of the modified insulin molecule.

Humalog 200 3 ml KwikPen is approved for use in pediatric patients with diabetes mellitus who require mealtime insulin, including via injection or insulin pump, with dosing individualized by a pediatric specialist based on body weight, meals, and blood glucose monitoring. Safety and efficacy in very young children (e.g. below the age range specified in local product labeling) have not been as extensively established, and use in this group requires closer specialist supervision. Hypoglycemia risk in children requires particular caution, including caregiver education on recognition and emergency treatment.